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Abstract
BACKGROUND: Metastatic bone disease is found in 8090%
of patients examined after death and is a serious problem in
everyday practice. The aim of the study was the evaluation of
the survival time of patients with bone metastases in relation to
the prognostic group and applied treatment.
MATERIAL AND METHODS: The authors analyzed 84 patients
treated in the Radiotherapy Division of Lower Silesian Oncolo-
gy Centre during the years 19972004. Radioisotope treatment
was conducted in the Department of Nuclear Medicine of the
4th Military Clinical Hospital in Wroc‡aw. The average age of the
patients was 53.1 years. The women differed in staging at the
moment of diagnosis. The patients were divided into two groups
with different clinical prognoses. In addition to systemic treat-
ment (biphosphonates, chemotherapy or hormonotherapy),
32 (38.1%) patients were treated with teletherapy and 20 (23.8%)
underwent radioisotope therapy. In 32 (38.1%) patients both
methods were applied. The analysis of results included the es-
timation of overall survival (OS) meaning the time of survival
from the onset of disease to one of the end points. End points
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of the observation were defined by the authors as the patients
death or last control visit. The Kaplan-Meier method was used.
RESULTS: The outcomes of the observation are closely con-
nected with particular prognostic groups. The Kaplan-Meiers
diagrams presented here indicate that teletherapy combined
with radioisotope therapy was the most beneficial for the pa-
tients with metastases in bones and other organs.
CONCLUSIONS: The best effects of the treatment measured
by overall survival were obtained with combined treatment: ra-
diotherapy and radioisotopes, in the group with bone and ex-
tra-skeletal metastases.
Key words: bone metastases, breast cancer, bone pain,
radiopharmaceuticals
Introduction
The treatment of bone metastases in the course of breast can-
cer is a serious challenge for contemporary oncology. Bone me-
tastases occur in about 2530% of all breast cancer cases and
80% of advanced cases [1]. To estimate the scale of this problem
we have to take into consideration the fact that about one million
new diagnoses of breast cancer are made every year, and about
400,000 women die annually from this neoplasm. The advances
achieved in treating patients with neoplasms have also changed
the attitude to women with bone metastases. Treating these pa-
tients means not only the alleviation of pain but also restoration of
their physical activity and, not infrequently, prolongation of life.
The prognosis in the case of bone metastases is unfavourable.
The presence of metastases means generalization of the disease
and in most cases determines the fate of the patient. Although
breast cancer patients with bone metastases live longer (on ave-
rage 2 years) than women with another distant metastases loca-
lization, only about 10% of these patients live 5 years or longer
from the time the diagnosis is made [1, 2].
In about 70% of cases bone metastases are accompanied by
pain that requires treatment [1]. Menacing complications are
pathological fractures, paralyses and pareses resulting from spi-
nal cord or nerve radices compression. 1020% of patients suffer
from hypercalcaemia [1]. All subjects present a considerable de-
crease in quality of life and depressive states.
139www.nmr.viamedica.pl
Ma‡gorzata Djabe‡ek-Macia et al., The effects of radioisotope therapy and radiotherapy
Short
communi-
cations
The main method of bone metastasis treatment is systemic
therapy combined with local and symptomatic therapy. The com-
bined treatment is a multidisciplinary therapy [1, 34, 58]. Radio-
therapy has been an acknowledged method of bone metastasis
treatment for many years. Palliative irradiation reduces pain ail-
ments in about 85% of cases, and in 50% of cases accomplishes
total pain remission [1]. The analgesic effect appears within the
first days after the beginning of radiotherapy and lasts for about
30 weeks [1, 9]. Currently the role of radioisotope therapy as
a separate method and a combined one with radiotherapy in dis-
seminated bone metastases treatment is increasing [3, 10, 1117].
The number of orthopaedic operations in patients with complica-
tions from bone metastases is increasing. Proper analgesic me-
dication and overcoming other symptoms of disseminated neo-
plasmatic disease are very important as well [1].
The aim of the study was to evaluate survival time in patients
with confirmed bone metastases in the course of breast cancer in
relation to the prognostic group and radiotherapeutic methods
applied.
Material and methods
The evaluated group consisted of 84 women treated in the
Division of Radiotherapy, Lower Silesian Oncology Centre during
the years 19972004. Radioisotope therapy was conducted in the
Department of Nuclear Medicine, 4th Military Clinical Hospital in
Wroc‡aw. Primarily the patients differed in clinical staging. Grade I
was confirmed in 4 patients (4.7%), grade II in 44 patients (52.3%),
grade IIIA in 8 patients (9.5%), grade IIIB in 8 patients (9.5%) and
grade IV in 8 patients (9.5%). 12 patients had unknown primary
clinical staging, but grade IV was excluded (Figure 1).
Bone metastases appeared at different periods of time after
neoplasmatic disease was diagnosed. The median of time when
bone metastases were found differed depending on clinical stag-
ing and was presented as follows: grade I on average after 55.5
months, grade II  on average after 34 months, grade IIIA on aver-
age after 28.5 months and grade IIIB on average after 23 months
(Figure 2).
For the purposes of the study the patients were divided into
two groups with different clinical prognoses.
The first group (38 subjects) comprised only of women with
bone metastases.
The second group (46 subjects) comprised of women with
metastases in parenchymatous organs or local recurrence apart
from bone metastases.
All subjects, after bone metastases recognition, underwent
treatment that fulfilled oncological standards and included hor-
monotherapy or chemotherapy, bisphosphonates and analgesic
drugs medication. Bone metastasis presence was confirmed with
radiographic examination and/or bone scintigraphy.
The results were analyzed with the use of the Kaplan-Meier
method.  The authors evaluated the overall time of survival (OS)
measured from the date of breast cancer diagnosis to the end
point. The authors defined an end point as the death of the pa-
tient or the date of the last control visit for living patients.
Groups characteristics
The first group contained 38 women with bone metastases
only. The average age was 58.5 years (range 39 to 73). 25 of the
patients were in postmenopausal period. The most frequent his-
tological type was the invasive ductal carcinoma (71% of cases),
lobular invasive carcinoma (13.2% of cases) or other histological
types (15.8% of cases). The average time from diagnosis to find-
ing bone metastases was 31 months in this group (range 0126
months). 70% of the patients presented bone lesions in two, three
or more localizations. The most common localizations were the
vertebral column and pelvis. Long and flat bones were not so of-
ten affected. Most of the metastases were presented as osteolyt-
ic lesions in RTG.
The second group, with 46 patients, presented metastases in
bones and parenchymatous organs or local recurrence. The ave-
rage age in this group was 48 years (range 3671). This group
also showed a prevalence of ductal invasive carcinoma present
in 82.6% of cases. The rest of the histological types presented as
follows: lobular invasive carcinoma  6.5% of cases and other
histological types 10.9% of cases. 32.6% of women were in post-
menopausal period. Bone metastases appeared in this group as
the first or successive metastatic localization. The median of time
from breast cancer diagnosis to bone metastases onset was
37.5 months (range 0264). The liver was the most often affected
parenchymatous organ (17 subjects). Lung metastases were
revealed in 8 patients, brain metastases in 4 patients, local recur-Figure 1. Graphic display of clinical staging.
Figure 2. Graphic presentation of the median of time from breast cancer
diagnosis to bone metastases appearance in months.
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rence in 6 patients, multiple localizations in 9 patients and other
localizations in 2 patients. By synchronic metastases the authors
meant metastatic changes in osseous and extra-osseous loca-
lizations at the time of diagnosis. Metachronic metastases were
considered when the time of finding metastases in bones was
different (usually earlier) from the moment of diagnosing metastas-
es in parenchymatous organs (Table 1).
Similarly to the first group bone metastases were mostly os-
teolytic lesions present in two or more localizations. Both groups
are characterized in Table 2.
Applied treatment
In both groups, apart from systemic treatment, radiotherapy
(32 subjects  38.12%), radioisotope therapy (20 subjects  23.8%)
or both methods (32 subjects  38.1%) were introduced (Table 3).
In the group of patients who underwent only radiotherapy, ir-
radiation was applied to localizations with the highest pain inten-
sity. Various fractionation schemes were used.
18.7% of the patients received a single fraction of 6 Gy
or 8 Gy, whilst 71.3% of the patients received fractionated radiother-
apy. A dose of 20 Gy was applied in 5 fractions, 21 Gy in 7 frac-
tions or 30 Gy in 10 fractions. The quantity of fractions and ap-
plied dose depended on general patient condition, extensiveness
and localization of metastases, predicted survival time and coex-
istent treatment. Radiotherapy was conducted using a Theratron
device with gamma 60Co rays, Philips device with X rays and pho-
ton radiation with energy of 46 MeV obtained in linear accelera-
tors (Neptun device, Co-line, CLINAC) [1823]. Before the irradia-
tion began, the target area was marked with the use of a simulator
(Roentgen device with optional TV view). Subsequently, a physi-
cist carried out the necessary calculations. Because of a lack of
acknowledged guidelines concerning irradiation area margins, the
authors used the area two vertebrae above and two vertebrae
below the lesion for metastases localized in the vertebral column.
For other localizations the irradiated area covered a visually de-
Table 2. Clinical characteristics of evaluated groups
Feature Number of patients (%)
Patients with bone Patients with bone and extra
metastases only (group I) osseous metastases (group II)
Number of patients in particular groups 38 46
Age
Median 58.5 48
Range 3973 3671
Clinical staging
I 3 (7.9%) 1 (1.2%)
II 19 (50%) 25 (54.3%)
IIIA 2 (5.3%) 6 (13%)
IIIB 4 (10.6%) 4 (8.7%)
IV 3 (7.9%) 5 (10.9%)
Unknown 7 (18.4%) 5 (10.9%)
Histopathological diagnosis
Invasive ductal carcinoma 27 (71%) 38 (82.6%)
Invasive lobular carcinoma 5 (13.2%) 3 (6.5%)
Others 6 (15.8%) 5 (10.9%)
Menopausal statu
Pre-menopausal 13 (34.2%) 31 (15%)
Post-menopausal 25 (65.8%) 67.4 (32.6%)
Table 3. Modes of applied treatment
Number  of patients (%)
Teletherapy Radioisotope Teletherapy and radioisotope
Patients with bone metastases only (group I) 8 (21%) 15 (39.5%) 15 (39.5%)
Patients with bone and extra osseous metastases (group II) 24 (52.2%) 5 (10.9%) 17 (36.9%)
Table 1. Synchronic and metachronic metastases
Localization Metastases
of metastasis Synchronic Metachronic
(no. of pts) (no. of pts)
Lung 7 1
Liver 3 14
Local recurrence 4 2
Brain 0 4
Multiple metastases 2 7
Others 0 2
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fined lesion with 2 cm margins. If a bone presented multiple
metastases, the target area covered the whole bone.
An important issue in radiotherapy planning is dose specifica-
tion. To avoid under dosing in lesions localized deep under the
skins surface such as the lumbar part of vertebral column, the
dose was not specified as a so called maximum, but at a parti-
cular depth.
In 20 subjects only radioisotope therapy was applied, whereas
32 women underwent both radiotherapy and radioisotope therapy.
The patients who qualified for radioisotope therapy had docu-
mented foci of increased osseous metabolism by means of scin-
tigraphy confirmed by another diagnostic method (RTG, CT or
NMR). The patients were subjected to a special therapeutic pro-
tocol concerning blood smear parameters. Minimal values pre-
sented as follows: WBC > 3.0G/L, platelet count > 100.000/ml,
creatinine level < 1.5 mg/dl.
Pregnancy, breast feeding and spine compression symptoms
were contraindications for radioisotope therapy. Radioactive iso-
tope could not be administered before two weeks following che-
motherapy or bisphosphonate application [15].
153Sm with an activity of 1 mCi/kg b.w. or 89Sr with an activity
of 4 mCi were administered. 52 patients underwent 120 radioisotope
therapies in total (105 with 153Sm and 15 with 89Sr). The number
of doses of radioisotope received by one patient ranged from 1 to 6.
16 women received a single radioisotope treatment, 16 patients
received two, 12 patients received 3 doses, 5 patients 4 doses,
2 patients 5 doses and 1 woman received 6 doses.
In patients who underwent teletherapy as well as radioisotope
therapy, the rules concerning treatment planning, margins and
doses were the same as described in the group treated only with
radiotherapy.
Results
The analysis of overall survival time and the time from bone
metastases to death or the date of the last control visit for living
patients was made. The data was evaluated with the use of
the Kaplan-Meier curve, the time was estimated in months.
Observation results are closely associated with particular prog-
nostic groups. The Kaplan-Meier diagrams (Figures 36) show
that the greatest benefit from the combined therapy (external beam
radiotherapy and radioisotope therapy) was shown both in pa-
tients with osseous and extra osseous metastases.
Discussion
The longer survival times in patients with bone and extra os-
seous metastases who underwent the combined therapy may re-
sult from applied systemic treatment. The application of chemo-
therapy followed guidelines for patients with extra osseous me-
tastases. Chemotherapy applied in patients with disseminated
breast carcinoma lengthens the stabilization period and time to
progression and improves the quality of life and survival time. This
has been proved by many randomized studies which evaluated
cytostatic treatment in metastatic breast cancer [24, 25]. The ad-
vantage of external beam radiotherapy and radioisotope therapy
association in patients with bone metastases in the course of
breast cancer has been stated [26]. Most randomized studies
that compared radioisotope therapy to radiotherapy or cytostatic
treatment concerned patients with bone metastases in the course
of prostate cancer. These studies showed greater efficacy of com-
bined treatment for pain ailments and life quality improvement [17].
The group of patients with metastases localized only in the
skeletal system presented worse effects. This can result from the
presence of negative oestrogen and progesterone receptors and
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Figure 3. Overall survival time (OS) from breast cancer diagnosis to death
or the last control visit in living patients in the group with bone metastases
(group I).
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Figure 4. Survival time from bone metastases diagnosis to death or the
last control visit in living patients with bone metastases only (group I).
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the application of inadequate systemic treatment. At the time these
patients were treated progesterone and oestrogen receptor de-
signating was not a routine procedure. The presence of these
receptors is a predictive factor for response to systemic treatment.
In patients with advanced breast cancer expressing oestro-
gen receptors palliative treatment, including hormonotherapy,
gives results comparable with chemotherapy. At the moment
of bone metastasis appearance hormonotherapy was applied.
As randomized studies and meta analysis show, the response to
this treatment could concern only about 10% of receptor negative
patients [2728].
Conclusions
The authors achieved the best effects with the combined treat-
ment: radiotherapy and radioisotopes, in patients with bone and
extra skeletal metastases.
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Figure 5. Overall survival time (OS) in patients from breast cancer diag-
nosis to death or the last control visit for living patients in group with bone
and extra-osseous metastases (group II).
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